Document Detail

Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial.
MedLine Citation:
PMID:  16753767     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the antihypertensive efficacy of L-arginine (L-Arg) repeated infusions in women affected by gestational hypertension. METHODS: The women were referred to obstetric units in order to assess their clinical conditions and to exclude the presence of severe fetal and/or maternal complications. Inclusion criteria were: maternal age range 16-45 years, diagnosis of gestational hypertension without proteinuria (patients normotensive until the 20th week), and gestational age ranging between 24 and 36 weeks. Each woman was allocated to receive either L-arginine (20 g/500 mL) or placebo treatment through an i.v. line. The infusion was carried out in the morning from 8 a.m. to 10 a.m. and it was repeated for the next four consecutive days. Systolic and diastolic blood pressure values as well as heart rate were recorded with the patient in an upright, seated position at 08:00, 12:00, 16:00 and 20:00 h. RESULTS: Maternal clinical features such as age, height, weight, and gestational age at inclusion were similar between groups. Both systolic and diastolic blood pressures were reduced by treatment, the effect of L-arginine being significantly higher than that of the placebo (systolic values F = 8.59, p < 0.005; diastolic values F = 3.36; p < 0.001). Twenty women assigned to the L-Arg group (32.2%) and 23 to the placebo group (37.7%) were concomitantly treated with antihypertensives before starting the study. Analyzing the subgroup of patients not receiving antihypertensive drugs we found that L-arginine was superior to placebo in lowering systolic (F = 5.42, p < 0.005) and diastolic (F = 2.20, p < 0.005) blood pressure values. CONCLUSIONS: In conclusion, these data support the use of L-Arg as an antihypertensive agent for gestational hypertension especially in view of the other beneficial effects nitric oxide donors display in pregnancy. Further, L-Arg seems well tolerated since in this sample none of the patients reported adverse effects requiring study interruption.
Isabella Neri; Valerio M Jasonni; Gian Franco Gori; Immacolata Blasi; Fabio Facchinetti
Related Documents :
10952467 - Urinary albumin excretion and 24-hour blood pressure as predictors of pre-eclampsia in ...
9790377 - Individually determined postpartum magnesium sulfate therapy with clinical parameters t...
2311817 - An 'admission challenge test' to predict severe hypertension in pregnancy?
16530917 - Arterial stiffness in preeclamptic and chronic hypertensive pregnancies.
373467 - Osmotic and nonosmotic control of vasopressin release.
9105767 - Influence of changes in ionized calcium on cardiovascular reactivity during hemodialysis.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians     Volume:  19     ISSN:  1476-7058     ISO Abbreviation:  J. Matern. Fetal. Neonatal. Med.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-06-06     Completed Date:  2006-11-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101136916     Medline TA:  J Matern Fetal Neonatal Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  277-81     Citation Subset:  IM    
Unit of Obstetrics and Gynecology, Mother-Infant Department, University of Modena and Reggio Emilia, Modena, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Arginine / therapeutic use*
Blood Pressure / drug effects
Gestational Age
Hypertension, Pregnancy-Induced / drug therapy*
Infusions, Intravenous
Labetalol / administration & dosage
Methyldopa / administration & dosage
Middle Aged
Reg. No./Substance:
0/Antihypertensive Agents; 0/Placebos; 36894-69-6/Labetalol; 555-30-6/Methyldopa; 74-79-3/Arginine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Atrial and ventricular septal defects - epidemiology and spontaneous closure.
Next Document:  A prospective randomized study comparing misoprostol and oxytocin for premature rupture of membranes...